Lineage Cell Treateutics，Inc.(NYSEAMERICAN：LCTX)從分析師那里獲得平均6美元的PT

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) has earned a consensus rating of "Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $6.00.

A number of equities analysts have recently commented on LCTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, March 11th. B. Riley started coverage on shares of Lineage Cell Therapeutics in a research note on Tuesday, June 14th. They set a "buy" rating and a $4.00 price objective for the company. Dawson James reiterated a "buy" rating and issued a $6.00 price target on shares of Lineage Cell Therapeutics in a report on Friday, March 11th. Finally, Maxim Group restated a "buy" rating and set a $5.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, May 13th.

Get

Lineage Cell Therapeutics

alerts:

Lineage Cell Therapeutics stock opened at $1.69 on Friday. Lineage Cell Therapeutics has a 52 week low of $1.10 and a 52 week high of $2.81. The stock has a market cap of $286.84 million, a P/E ratio of -5.83 and a beta of 1.60.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.05). Lineage Cell Therapeutics had a negative return on equity of 27.43% and a negative net margin of 528.23%. The business had revenue of $5.24 million for the quarter, compared to analyst estimates of $12.07 million. Analysts predict that Lineage Cell Therapeutics will post -0.17 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. Wealth Architects LLC acquired a new stake in Lineage Cell Therapeutics in the 1st quarter valued at $25,000. Straight Path Wealth Management bought a new position in Lineage Cell Therapeutics in the fourth quarter valued at approximately $40,000. Mirabella Financial Services LLP bought a new position in shares of Lineage Cell Therapeutics in the 1st quarter valued at $29,000. Lazard Asset Management LLC bought a new position in shares of Lineage Cell Therapeutics in the 4th quarter valued at $52,000. Finally, ProShare Advisors LLC grew its position in Lineage Cell Therapeutics by 70.5% during the 4th quarter. ProShare Advisors LLC now owns 27,397 shares of the company's stock worth $67,000 after acquiring an additional 11,326 shares during the last quarter. Hedge funds and other institutional investors own 45.12% of the company's stock.

Lineage Cell Therapeutics Company Profile (Get Rating)

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Featured Articles

• Get a free copy of the StockNews.com research report on Lineage Cell Therapeutics (LCTX)
• 3 Education Stocks to Enroll in This Summer
• The Institutions Get Comfortable With The Lovesac Company
• McDonald's Might Just Be The Best Recession Proof Stock
• Basset Furniture Quietly Proves Its Value
• Earnings Revisions: Why You Shouldn't Count On A Rebound In Stocks ... Yet

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.